Is Elderly ICU Patient More Prone To Pneumonia?* T he elderly population-as defined as 65 years old or older-represents about 13% of the U.S. population and is expected to grow to 19% by 2030 due to increasing life expectancy (1, 2) . Older age per se and increasing age within the elderly range are independent risk factor for mortality in the ICU (1) . Additionally, patients' comorbidities such as congestive heart failure (CHF) and chronic obstructive pulmonary disease (COPD), primary admission diagnoses, premorbid cognitive and functional state, and severity state at admission are major contributors of morbidity and mortality in critically ill patients (3) (4) (5) (6) .
Within nosocomial infections, pneumonia is one of the most common in the ICU setting; the prevalence may go beyond 20-fold in mechanically ventilated ICU patients compared with all other hospitalized patients (7, 8) . Pneumonia is reportedly the most lethal nosocomial infection, but whether it increases mortality per se is controversial, especially when treated appropriately (9, 10) . Mortality attributable to pneumonia may depend on severity status of disease at admission, premorbid conditions (11), microorganisms responsible for pneumonia (9, 12, 13) , and the ICU environment (6, 14, 15) . Patient-specific factors, such as age and preexisting disease (6, 16) , and care-related factors, such as head-of-the-bed angle, use of standardized protocols for mechanical ventilation, oral hygiene, and selective digestive decontamination (17) (18) (19) , play important roles in prognosis. Neurological status at admission adds specific risks and complicates progress. Neurological compromise often results in loss of airway protective reflexes with subsequent aspiration. Pneumonia often ensues neurological deterioration.
In this issue of Critical Care Medicine, Blot et al and the European Union Ventilator-Associated Pneumonia (EU-VAP) Study Investigators (20) reported new results on prevalence, risk factors, and mortality of ventilator-associated pneumonia (VAP) in adult patients with specific focus on the elderly. In this secondary analysis of a previous multicenter prospective cohort (EU-VAP) (21), investigators did not find an increased risk of VAP in the elderly population. Neurological, cardiovascular, metabolic, and renal/hepatic organ-system failures at admission were found to be independently associated with VAP, but within those organ-system failures, CHF was definitely the strongest contributor in specifically elderly population. VAP etiology was mostly due to Gram-negative bacteria, mainly attributed to the Enterobacteriaceae family pathogens in the elderly. Both methicillin-susceptible and methicillinresistant Staphylococcus aureus pneumonias were at similar frequency within the spectrum of all adult patients. Interestingly, Streptococcus pneumoniae-related lower respiratory tract infections were at lower rate in the elderly patient population compared with middle-aged adults. Although these lower pneumonia rates were to be related to elderly vaccination programs, data on vaccination status were not available in the EU-VAP Study database.
Blot et al (20) reported independent risk factors of mortality in patients with VAP. Older age (both 65-to 74-yr olds and ≥ 75 yr olds), septic shock, high-risk pneumonia pathogens (i.e. methicillin-resistant S. aureus [MRSA] , Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia), and diabetes mellitus were reported as the main contributors of mortality. Being a secondary analysis report, neither data on the resistance patterns of pathogenic bacteria nor diabetes care was known to the investigators. Similarly, the duration and management details of septic shock and pneumonia were not available.
Prevalence of CHF exacerbations in the elderly population is one of the most common causes of hospitalization due to decreased ability to respond to myocardial stressors. An early assessment of cardiac functionality and immediate treatment of CHF would improve outcomes in the intensive care management of the elderly. CHF treatment modalities, which have been delivering mortality benefits in elderly patients with left ventricular systolic dysfunction, are angiotensin-converting-enzyme inhibitors or angiotensin II receptor blockers. β-blockers, aldosterone antagonists, and-for patients who cannot tolerate ACE inhibitors or ARBs-a combination of hydralazine and nitrates (22) .
Chronic lung disease contributes to VAP, especially in medical ICU patients (23, 24) such risk may go as high as 33% in mechanically ventilated patients with COPD. VAP may be more serious and require longer duration of mechanical ventilation (24) . Noninvasive ventilation can be considered an important tool to decrease the needs of intubation and further complications. However, noninvasive ventilation is contraindicated in patients with neurological compromise because of increased risk of aspiration.
The report by Blot et al (20) enlightens us about various aspects of VAP in the elderly ICU patient population, but due to being a secondary analysis of a dataset with different primary focus, it leaves us with some incompletely answered questions. To have a complete understanding of the epidemiology of VAP in elderly ICU patients, one needs to know detailed answers to the following issues: Answers to these questions may give us a complete understanding of the development of VAP and may guide us for better care of the elderly.
